Ask AI
ProCE Banner Activity

Pancreatic Cancer Progress: Enhancing Knowledge and Optimizing Innovations in Patient Care

Slideset

Download these slides on current and emerging strategies for the management of pancreatic cancer, including first-line and second-line chemotherapy options, based on key clinical trial data, as well as management of treatment-related toxicities, the evolving role of targeted therapies, and future directions.

Released: December 01, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Ipsen Biopharmaceuticals, Inc.

Ipsen Biopharmaceuticals Inc

Target Audience

This program is intended for community oncologists, residents, fellows, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals managing pancreatic cancer patients.

Program Learning Goal

This program aims to improve learners’ knowledge and competence regarding managing mPDAC, highlighting patient selection for novel treatment strategies, adverse event management, and multidisciplinary care.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate current evidence and guideline recommendations on the use of first-line treatment into treatment plans for patients with metastatic pancreatic cancer.

  • Distinguish between first-line and subsequent treatment strategies to help determine optimal personalized care for patients with metastatic pancreatic cancer.

  • Monitor and appropriately manage chemo-induced adverse events in collaboration with the multidisciplinary team.

Faculty Disclosure

Primary Author

Paul E. Oberstein, MD: consultant/advisor/speaker: Ipsen, Janssen, Lilly Oncology, Revolution Medicine.

Mark O’Hara, MD: consultant/advisor/speaker: Merus, Revolution Medicine; researcher (paid to institution): Akamis, Bristol Myers Squibb, Celldex, Elicio, Geistlich, Genmab, Hibercell, Merck, Natera, Revolution Medicine, Verastem.

Zev A. Wainberg, MD: consultant/advisor/speaker: AbbVie, Alligator, Amgen, Arcus, AstraZeneca, Bayer, BeOne, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono, Gilead, Ipsen, Janssen, Jazz, Lilly, Merck, Novartis, Pfizer, Phanes, Revolution Medicine.